GE Healthcare backed research could make stem cell production faster and cheaper

By Gareth Macdonald

- Last updated on GMT


Related tags Cell biology Stem cell

A human plasma protein could make producing pluripotent stem cells cheaper and faster according to academics in the UK and Sweden and partner GE Healthcare.

The scientists made the claim in a new paper that describes how the protein - Inter-alpha inhibitor - allows cells to attach to the plastic surfaces of culture vessels directly rather than via a substrate, which is the most commonly used approach.

Lead author Sara Pijuan-Galitó told us "this new method could reduce cost, time and difficulties in automated and large-scale culture methods for human pluripotent stem cells​."

She added that "we do not have an estimate on the cost reduction yet, but we are currently contacting pharmaceutical companies to generate quotes for the cost of Inter-alpha inhibitor.

"With this paper published we hope to raise interest in this human blood-derived protein and its effects on cell attachment and growth.

"The key feature of this method is its simplicity, making automated cell culture much faster, easier and cost-effective. Moreover, this method also shows improved survival in harsh conditions, therefore achieving higher recovery rates​." 

Medical research 

The plan now is to combine the protein with hydrogel technology to develop differentiation control methods according to co-author Cathy Merry. She predicted that, in addition to facilitating industrial stem cell production, the approach will aid disease research.

This will help research into many diseases but our focus is on understanding rare conditions like Multiple Osteochondroma at the cellular level.

“Our aim is to replicate the three dimensional environment that cells experience in the body so that our lab-bench biology is more accurate in modelling diseases​."

The research​ was co-funded by GE Healthcare.

Source: Nature Communications

Title: Human serum-derived protein removes the need for coating in defined human pluripotent stem cell culture

Author: Sara Pijuan-Galitó et al

DOI 10.1038/NCOMMS12170

Related news

Show more

Related products

show more

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Related suppliers

Follow us


View more